Citigroup Inc Verve Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 56,451 shares of VERV stock, worth $256,852. This represents 0.0% of its overall portfolio holdings.

Number of Shares

56,451

Previous 42,163 33.89%

Holding current value

$256,852

Previous $205,000 33.17%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$4.4 - $7.86 $62,867 - $112,303	14,288 Added 33.89%	56,451 $273,000
Q2 2024 Aug 12, 2024	SELL	$4.76 - $12.79 $1.59 Million - $4.27 Million	-333,896 Reduced 88.79%	42,163 $205,000
Q1 2024 May 10, 2024	BUY	$10.81 - $17.96 $2.51 Million - $4.17 Million	232,344 Added 161.67%	376,059 $4.99 Million
Q4 2023 Feb 09, 2024	BUY	$8.84 - $18.7 $203,726 - $430,960	23,046 Added 19.1%	143,715 $2 Million
Q3 2023 Nov 09, 2023	BUY	$11.42 - $20.82 $355,458 - $648,043	31,126 Added 34.76%	120,669 $1.6 Million
Q2 2023 Aug 10, 2023	SELL	$13.34 - $19.9 $5.4 Million - $8.05 Million	-404,476 Reduced 81.87%	89,543 $1.68 Million
Q1 2023 May 11, 2023	BUY	$14.3 - $24.01 $4.7 Million - $7.88 Million	328,340 Added 198.18%	494,019 $7.12 Million
Q4 2022 Feb 09, 2023	SELL	$17.85 - $40.7 $36,431 - $83,068	-2,041 Reduced 1.22%	165,679 $3.21 Million
Q3 2022 Nov 10, 2022	BUY	$15.63 - $41.49 $2.49 Million - $6.62 Million	159,472 Added 1933.46%	167,720 $5.76 Million
Q2 2022 Aug 10, 2022	SELL	$11.14 - $23.17 $338,923 - $704,924	-30,424 Reduced 78.67%	8,248 $126,000
Q1 2022 May 12, 2022	SELL	$20.92 - $39.36 $1.73 Million - $3.25 Million	-82,485 Reduced 68.08%	38,672 $882,000
Q4 2021 Feb 10, 2022	BUY	$31.94 - $54.82 $3.81 Million - $6.54 Million	119,343 Added 6579.0%	121,157 $4.47 Million
Q3 2021 Nov 10, 2021	BUY	$46.0 - $73.99 $83,444 - $134,217	1,814 New	1,814 $85,000

Others Institutions Holding VERV

# of Institutions

186

Shares Held

73.3M

Call Options Held

85K

Put Options Held

215K

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $273M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account